CD30+ anaplastic large cell lymphoma (ALCL) represents a novel lymphom
a entity at the borderline between Hodgkin's disease and non-Hodgkin's
lymphomas. Phenotypic, genotypic, and karyotypic analyses have shown
that ALCL are heterogeneous in cellular origin, and may be conceived a
s malignancies derived from activated, mainly T- or B-lymphoid cells,
in some instances with an immature genotype. Epstein-Barr virus genome
s and gene products, most notably the transformation-associated latent
membrane protein (LMP), have been detected in a proportion of cases,
and some cutaneous ALCL proved to harbor complete or incomplete HTLV-1
proviruses. These findings suggest that both EBV and HTLV-1, which ar
e powerful inducers of CD30 expression in lymphoid cells in vitro, may
contribute to the pathoetiology of ALCL.